A Study of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis (IPF)


About this study

The main objectives of this study are to determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF), to determine the difference in change in Quality of Life (QoL) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF), and to determine if there is an enduring effect in 6MWD, QoL and lung function from pulmonary rehabilitation (PR) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients being treated with a stable dose of nintedanib 150 mg BID for up to 30 months. 
  • Patients who have recently started nintedanib 150 mg BID and have started by the day of randomization must be on nintedanib 150 mg BID a minimum of 10 days by the first day of pulmonary rehabilitation. 
  • Age ≥ 40 years at screening.
  • Women of childbearing potential (WOCBP)* must be ready and able to use highly effective methods of birth control per ICH M3 (R2) (R17-1399) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient consent form.
  • Signed and dated written informed consent in accordance with ICH-GCP (International Council on Harmonization and Good Clinical Practice) and local legislation prior to admission to the trial.
  • Confirmed diagnosis of IPF according to 2011 ATS/ERS/JRS/ALAT guidelines by lung biopsy or HRCT (based upon INPULSIS criteria (c02098775-02, c02155574-02), (if biopsy only or HRCT done > 24 months prior to screening, a new HRCT to be done after consent and prior to or up to 7 days after Visit 2 for quantitative lung fibrosis score (QLF) for disease characterization).
  • Forced Vital Capacity (FVC) ≥ 45% of predicted by the NHANES equation (R04-1001) or equivalent (after discussion with Clinical Monitor), historical within past 30 days can be used. Carbon monoxide Diffusion Capacity (DLCO) (corrected for hemoglobin [Hgb]) 30-79% of predicted.
  • FEV1/FVC greater than/equal to .7.
  • Physically capable of performing both a 6 minute walk test and work rate cycle ergometry (sub-study patients), must successfully complete the practice tests for the 6 minute walk test, per the instructions. Potential sub-study patients that require supplemental oxygen or cannot complete the incremental work rate cycle ergometry test will not participate in the sub-study, but will qualify for the main study.

* A woman is considered of childbearing potential (WOCBP); i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile.  Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.  A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

Exclusion Criteria:

  • Major surgery (major according to the investigator’s assessment) performed within 12 weeks prior to randomization or planned within 6 months after screening; e.g., hip replacement which could interfere with the ability to participate in pulmonary rehabilitation.
  • Any documented active or suspected malignancy or history of malignancy within 3 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  • Previous enrolment in this trial.
  • Currently enrolled in another interventional investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s).
  • Chronic alcohol or drug abuse or any condition that, in the investigator’s opinion, makes them an unreliable trial patient or unlikely to complete the trial.
  • Women who are pregnant, nursing, or who plan to become pregnant in the trial.
  • Previous participation in pulmonary rehabilitation program within 45 days prior to signing consent


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Teng Moua, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer